Clinical trials: Cardiovascular Event
Arteriosclerosis, Hypercholesterolaemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk.
- Trial name
- NCT06008756
- Testing
- Enlicitide Decanoate
- Where
- 669 sites in United States, Argentina and 27 more
- Volunteers
- 14,550 people
- Sponsor
- Merck Sharp & Dohme LLC
Intracerebral Infarcts, Ischemic Stroke
Discharge Educational Strategies for Reduction of Vascular Events
DESERVE is a discharge education study using health workers to enroll and randomly assign 800 subjects diagnosed with TIA, or mild stroke to either risk factor education or usual care.
- Conditions
- Intracerebral Infarcts, Ischemic Stroke, Hemorrhagic Strokes, TIA's
- Trial name
- DESERVE (NCT01836354)
- Testing
- DESERVE education
- Where
- 3 sites in United States
- Volunteers
- 552 people
- Sponsor
- NYU Langone Health
Heart Failure With Preserved Ejection Fraction
CHIP in Endothelial Dysfunction Associated With HEpEF
This study aims at identifying processes that are deregulated in blood cells by Clonal Hematopoiesis of Indeterminate Potential (CHIP) which are involved in the development of heart failure with preserved ejection fraction…
- Trial name
- CHiEF (NCT05828888)
- Volunteers
- 80 people
- Sponsor
- University Hospital, Bordeaux
Hypertension
Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)
The purpose of this study is to establish the safety of clevidipine in the treatment of perioperative hypertension. Approximately 250-500 patients with perioperative hypertension undergoing coronary artery bypass grafting (CABG)…
- Trial name
- ECLISPE-SNP (NCT00093912)
- Testing
- clevidipine, sodium nitroprusside
- Where
- 29 sites in United States
- Volunteers
- 739 people
- Sponsor
- The Medicines Company
Myocardial Infarction
Carotid Intima-media Thickness as Cardiovascular Mortality Predictor in Peritoneal Dialysis Patients
Cardiovascular (CV) disease is the main cause of death in patients on dialysis. The aim of this study is the long-term prognostic values of carotid intima-media thickness and coronary flow reserve in cardiovascular mortality of…
- Trial name
- NCT02938767
- Where
- Turkey (Türkiye)
- Volunteers
- 57 people
- Sponsor
- Istanbul University
Myocardial Infarction, Autonomic Dysfunction
The Usefulness of Assessing Heart Rate Variability in Patients With Acute Myocardial Infarction
Aims heart rate variability (HRV) assessment in patients with acute myocardial infarction who undergo primary percutaneous coronary intervention (PCI); measurement of HRV using a device approved for medical use in Europe…
- Trial name
- HeaRt-V-AMI (NCT05098977)
- Testing
- Heart rate variability measurement, Percutaneous coronary intervention
- Where
- Romania
- Volunteers
- 200 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Atherosclerosis
Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid
In this study researchers want to gain more information on treatment patterns of patients treated with Xarelto in combination with acetylsalicylic acid (ASA). Both drugs reduce the risk of blood clots via different pathways.
- Trial name
- XATOA (NCT03746275)
- Testing
- Rivaroxaban (BAY59-7939, Xarelto), Acetylsalicylic acid
- Where
- 18 sites in Argentina, Brazil and 16 more
- Volunteers
- 5,798 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
A Study of Cardiovascular Events iN Diabetes Plus
ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes…
- Trial name
- ASCEND PLUS (NCT05441267)
- Testing
- Semaglutide Oral Tablet
- Where
- United Kingdom
- Volunteers
- 21,296 people
- Sponsor
- University of Oxford
Colorectal Adenocarcinoma, Oesogastric
Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients
The purpose of this study is to assess the incidence of cardiovascular events in patients with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin after an episode of cardiac angina-related…
- Trial name
- NCT04894123
- Testing
- Trifluridine/Tipiracil, Oxaliplatin
- Where
- 11 sites in France
- Volunteers
- 1 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Atrial Fibrillation, Hemorrhage
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
This study is being conducted to collect data on the management of major bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.
- Trial name
- NCT02149303
- Testing
- Dabigatran 75 mg, Dabigatran 150 mg
- Where
- 5 sites in United States
- Volunteers
- 191 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Retinal Disorder
DETECT and Retinal Outcomes in Hypertension
The purpose of this study is to study the impact of blood pressure on cognitive performance.
- Conditions
- Hypertension, Retinal Disorder, Cognitive Impairment
- Trial name
- NCT01815567
- Where
- United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Emory University
Rheumatoid Arthritis
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events with tocilizumab in comparison to etanercept in participants with rheumatoid arthritis (RA).
- Trial name
- NCT01331837
- Testing
- Etanercept, Tocilizumab
- Where
- 428 sites in United States, Argentina and 29 more
- Volunteers
- 3,080 people
- Sponsor
- Hoffmann-La Roche
Acute Myocardial Infarction, Cardiac Rehabilitation
Effect of Digital Therapeutics for Cardiac Rehabilitation in Patients With Acute Myocardial Infarction
This study adopts a multicenter, open-label, randomized controlled clinical study, with Jiangsu Provincial People's Hospital as the leading unit, and the other 13 hospitals as cooperative units.
- Trial name
- NCT06772337
- Testing
- digital cardiac rehabilitation, Regular Treatment
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cardiac Events
MACE CDS Software Master Enrollment Protocol
This protocol will collect real world EHR data to support the product development life cycle activities associated with developing the Major Adverse Cardiac Events (MACE) Clinical Decision Support (CDS) software.
- Trial name
- NCT06257628
- Testing
- Index Event
- Where
- 3 sites in United States
- Sponsor
- Beckman Coulter, Inc.
Ischemic Stroke, Mild
ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)
The purpose of this study is to investigate the safety and efficacy of rhPro-UK (35mg) versus standard medical treatment in acute mild ischemic stroke within 4.5 hours of symptom onset.
- Conditions
- Ischemic Stroke, Mild, Thrombosis
- Trial name
- PUMICE (NCT05507645)
- Testing
- Recombinant Human Prourokinase for Injection (rhPro-UK), standard medical treatment
- Where
- 89 sites in China
- Volunteers
- 1,446 people
- Sponsor
- Beijing Tiantan Hospital
Arrythmia
Assessment of Adverse Cardiac Events Using Local Anesthesia With Adrenaline
The use of vasopressor supplement materials to local anesthetics is commonly used in procedures in various fields of dentistry, ENT (ear, nose, and throat), Plastic Surgery, Hand surgery and gastroenterology.
- Trial name
- NCT02738567
- Testing
- patients undergoing surgery or medical procedure
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Geographic Mismatch, Short-Term
Geographic Mismatch as A Predictor of Short-Term Major Adverse Cardiovascular Events Following Long Coronary Stent Implantation
This study aims to evaluate whether geographic mismatch is an independent predictor of short-term major adverse cardiovascular events following long coronary stent implantation.
- Conditions
- Geographic Mismatch, Short-Term, Major Adverse Cardiovascular Events, Long Coronary Stent Implantation
- Trial name
- NCT07890181
- Testing
- Coronary Stent Implantation
- Where
- Egypt
- Volunteers
- 650 people
- Sponsor
- Sohag University
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
The CARDIOPROTECT Trial
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care…
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
- Trial name
- NCT07654426
- Testing
- Dexrazoxane, Doxorubicin, Liposomal Doxorubicin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cardiovascular Disease
PeriOperative ISchemic Evaluation-2 Trial
Major surgeries not involving the heart are common, and major heart problems during or after such surgeries represent a large population health problem.
- Trial name
- POISE-2 (NCT01082874)
- Testing
- Active Clonidine, Active ASA
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 10,010 people
- Sponsor
- Hamilton Health Sciences Corporation
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade
- Trial name
- NCT02269592
- Where
- 7 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.